

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Highly Specialised Technologies Evaluation

Setmelanotide for treating obesity caused by LEPR or POMC deficiency ID3764

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Rhythm Pharmaceuticals (setmelanotide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • BEAT • British Obesity Society • British Obesity Surgery Patients Association • Contact • Find a Cure • Genetic Alliance UK • Healthier Weight Centres • Muslim Council of Britain • National Centre for Eating Disorders • National Obesity Forum • Obesity Health Alliance • Obesity UK • Overeaters Anonymous • South Asian Health Foundation • Specialised Healthcare Alliance • Weight Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • British Association of Endocrine and Thyroid Surgeons • British Geriatrics Society • British Nutrition Foundation • British Obesity Surgery Society • Nutrition Society • Obesity Management Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • TREND UK 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Services Division • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Alissa Healthcare Research (orlistat) • Almus Pharmaceuticals (orlistat) • Cheplapharm Arzneimittel (orlistat) • Crescent Pharma (orlistat) • GlaxoSmithKline Consumer Healthcare (orlistat) • Teva UK (orlistat) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Public Health Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research

Provisional stakeholder list for the proposed highly specialised technologies evaluation of setmelanotide for treating obesity caused by LEPR or POMC deficiency ID3764 Issue date: June 2020

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Clinical Pharmacy Association • UK Health Forum <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Endocrinology, University Hospital Birmingham Foundation Trust • Department of Health and Social Care • Great Ormond Street Hospital Metabolic Unit • National Hospital for Neurology and Neurosurgery Charles Dent Metabolic Unit • NHS England • Salford Royal NHS Foundation Trust Mark Holland Metabolic Unit • Willink Unit, Genetic Medicine, Central Manchester Foundation Trust 	<p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Faculty of Public Health Medicine • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the evaluation; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier, respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research

Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee